Comparison Between Efficacy of Trelagliptin and Sitagliptin in Type II Diabetic Patients

Launched by KHYBER MEDICAL COLLEGE, PESHAWAR · Jul 9, 2025

Keywords

ClinConnect Summary

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder associated with significant microvascular and macrovascular complications. In many patients, blood sugar levels remain above target despite treatment with metformin, which is the usual first-line therapy. Additional treatments are often required to achieve optimal glycemic control.

Dipeptidyl peptidase-4 (DPP-4) inhibitors are oral medications used in managing T2DM. They work by preventing the breakdown of incretin hormones, which help regulate insulin secretion and lower blood glucose levels. Most DPP-4 inhibitors, including ...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • • Type 2 Diabetic patients visiting Medical OPD
• • Patients already maintaining lifestyle modifications and on metformin monotherapy, but not achieving target HbA1c levels.
• • Patients who require treatment with a DPP-4 inhibitors
• • Patients with baseline HbA1c \> 6.5% and \< 10%
• • Patients willing to provide written informed consent prior to recruitment
• Exclusion Criteria:
• • • Type 1 Diabetic Patients
• • Patients already using Trelagliptin for type 2 diabetes
• • Patients with severe renal impairment (eGFR \< 30ml/min/1.73m2 or on dialysis)
• • Patients with Serious Heart disease or Cerebrovascular disease
• • Patients with Serious Pancreatic or blood disease
• • Patients with malignancy
• • Patients with history of hypersensitivity to DPP-4 inhibitors
• • Patients with history of gastrointestinal resection
• • Pregnant, Breast feeding or planning to be pregnant patients
• • Patients participating in other clinical studies
• • Patients assessed as ineligible by researchers due to any other reason